***Meta-analysis of time-to-event data***

*For the trial of Gemcitabine in combination with Oxaliplatin for pancreatic cancer (Louvet et al 2005), please complete the following as far as possible for the outcome Overall Survival and enter data into the excel spreadsheet (link below) to find logHR and SE for this trial*

[*http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls*](http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls)

1. ***Data Extraction***

|  |  |  |
| --- | --- | --- |
| **Data to extract** | **Research** | **Control** |
| Randomisation ratio (e.g. 1:1) |  |  |
| Number randomised |  |  |
| Number analysed |  |  |
| Observed events |  |  |
| Logrank expected events |  |  |
| Logrank Variance (V) |  | |
| Logrank observed minus expected events (O-E) |  | |
| HR, CI (with level e.g. 95%) or standard error or variance (specify method e.g. Cox model) |  | |
| Test statistic, 2-sided p-value and name of test (e.g. logrank) |  | |
| Advantage to research or control? |  | |
| Actuarial or Kaplan Meier curves presented |  | |
| Numbers at risk reported? |  | |
| Follow-up details (minimum and maximum) |  | |

1. ***Survival curve estimates***

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Timepoint** | | | | | | | | |
| **0** |  |  |  |  |  |  |  |  |
| Survival | Research |  |  |  |  |  |  |  |  |  |
| probability | Control |  |  |  |  |  |  |  |  |  |
| Numbers | Research |  |  |  |  |  |  |  |  |  |
| at risk\* | Control |  |  |  |  |  |  |  |  |  |

\*if given

1. ***Results***

|  |  |  |  |
| --- | --- | --- | --- |
| **Method** | **Comments** | **logHR** | **SE(logHR)** |
| Cox model HR with CI |  |  |  |
| Logrank p-value with observed events |  |  |  |
| Kaplan Meier Curve |  |  |  |
| Other |  |  |  |